Trial Profile
A Phase I/II Trial to Evaluate the Safety and Tolerability of Clazakizumab (Anti-IL-6 Monoclonal) to Eliminate Donor Specific HLA Antibodies (DSAs) and Improve Transplant Rates in Highly-HLA Sensitized Patients Awaiting Renal Transplant
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Clazakizumab (Primary) ; Alemtuzumab; Mycophenolate mofetil; Prednisone; Tacrolimus
- Indications Renal transplant rejection
- Focus Adverse reactions; Therapeutic Use
- 12 Mar 2024 Planned End Date changed from 30 Dec 2024 to 30 Jul 2025.
- 12 Mar 2024 Planned primary completion date changed from 30 Dec 2024 to 30 Jul 2025.
- 10 Mar 2023 Planned End Date changed from 30 Dec 2023 to 30 Dec 2024.